Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis

Authors: Bingran Yu, Xuting Zhi, Qiong Li, Tao Li, Zhiqiang Chen

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

The incidence of HBV-negative and HCV-negative hepatocellular carcinoma (NBNC-HCC) is significantly increasing. However, their clinicopathologic features and prognosis remain elucidated. Our study aimed to compare the clinicopathologic characteristics and survival outcomes of NBNC-HCC with hepatitis virus-related HCC.

Method

A literature review was performed in several databases, including PubMed, Embase, Cochrane Library and Web of Science, to identify the studies comparing NBNC-HCC with HBV-positive HCV-negative HCC (B-HCC), HBV-negative HCV-positive (C-HCC) and/or HBV-positive HCV-positive HCC (BC-HCC). The clinicopathologic characteristics and survival outcomes were extracted and pooled to access the difference.

Results

Thirty-two studies with 26,297 patients were included: 5390 patients in NBNC-HCC group, 9873 patients in B-HCC group, 10,848 patients in C-HCC group and 186 patients in BC-HCC group. Patients in NBNC-HCC group were more liable to be diagnosed at higher ages, but with better liver functions and lighter liver cirrhosis. Comparing to B-HCC and C-HCC groups, although NBNC-HCC group was prone to have larger tumor sizes, it did not have more advanced tumors. Meanwhile, there were no significant differences in both 5-year and 10-year disease-free survival and overall survival between NBNC-HCC group and B-HCC or C-HCC group.

Conclusions

Our meta-analysis revealed patients with NBNC-HCC had as worse prognosis as those with hepatitis virus-related HCC. More attention should be paid on patients with non-alcoholic steatohepatitis or metabolic syndromes to prevent the incidence of NBNC-HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018;391(10127):1301–14. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018;391(10127):1301–14.
2.
go back to reference Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev. 2018;27(3):205–12.PubMedPubMedCentral Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev. 2018;27(3):205–12.PubMedPubMedCentral
3.
go back to reference Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, Ni YH, Chen CJ, Chen DS. Taiwan Childhood HCCSG: Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11(21):7953–7.PubMed Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, Ni YH, Chen CJ, Chen DS. Taiwan Childhood HCCSG: Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11(21):7953–7.PubMed
4.
go back to reference Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8(2):192–9.PubMed Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8(2):192–9.PubMed
5.
go back to reference Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.PubMed Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.PubMed
6.
go back to reference Ganne-Carrie N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70(2):284–93.PubMed Ganne-Carrie N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70(2):284–93.PubMed
7.
go back to reference Sasaki K, Shindoh J, Nishioka Y, Margonis GA, Sugawara T, Andreatos N, Hashimoto M, Pawlik TM. Impact of Viral Etiology on Postoperative De Novo Recurrence After Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Surg. 2017;21(3):487–95.PubMed Sasaki K, Shindoh J, Nishioka Y, Margonis GA, Sugawara T, Andreatos N, Hashimoto M, Pawlik TM. Impact of Viral Etiology on Postoperative De Novo Recurrence After Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Surg. 2017;21(3):487–95.PubMed
8.
go back to reference Naito S, Imamura H, Tukada A, Matsuyama Y, Yoshimoto J, Sugo H, Ishizaki Y, Kawasaki S. Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status. Liver Int. 2014;34(5):802–13.PubMed Naito S, Imamura H, Tukada A, Matsuyama Y, Yoshimoto J, Sugo H, Ishizaki Y, Kawasaki S. Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status. Liver Int. 2014;34(5):802–13.PubMed
9.
go back to reference Yamanaka N, Tanaka T, Tanaka W, Yamanaka J, Yasui C, Kuroda N, Takada M, Okamoto E. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer. 1997;79(8):1509–15.PubMed Yamanaka N, Tanaka T, Tanaka W, Yamanaka J, Yasui C, Kuroda N, Takada M, Okamoto E. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer. 1997;79(8):1509–15.PubMed
10.
go back to reference Wakai T, Shirai Y, Yokoyama N, Nagakura S, Hatakeyama K. Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma. Eur J Surg Oncol. 2003;29(3):266–71.PubMed Wakai T, Shirai Y, Yokoyama N, Nagakura S, Hatakeyama K. Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma. Eur J Surg Oncol. 2003;29(3):266–71.PubMed
11.
go back to reference Cescon M, Cucchetti A, Grazi GL, Ferrero A, Vigano L, Ercolani G, Ravaioli M, Zanello M, Andreone P, Capussotti L, et al. Role of Hepatitis B Virus Infection in the Prognosis After Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis A Western Dual-Center Experience. Arch Surg. 2009;144(10):906–13.PubMed Cescon M, Cucchetti A, Grazi GL, Ferrero A, Vigano L, Ercolani G, Ravaioli M, Zanello M, Andreone P, Capussotti L, et al. Role of Hepatitis B Virus Infection in the Prognosis After Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis A Western Dual-Center Experience. Arch Surg. 2009;144(10):906–13.PubMed
12.
go back to reference Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol. 2011;9:108.PubMedPubMedCentral Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol. 2011;9:108.PubMedPubMedCentral
13.
go back to reference Li T, Qin L-X, Gong X, Zhou J, Sun H-C, Qiu S-J, Ye Q-H, Wang L, Fan J. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 2013;119(1):126–35.PubMed Li T, Qin L-X, Gong X, Zhou J, Sun H-C, Qiu S-J, Ye Q-H, Wang L, Fan J. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer. 2013;119(1):126–35.PubMed
14.
go back to reference Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer. 2013;4(6):502–13.PubMedPubMedCentral Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer. 2013;4(6):502–13.PubMedPubMedCentral
15.
go back to reference Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 2015;261(3):513–20.PubMed Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 2015;261(3):513–20.PubMed
16.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.
17.
go back to reference Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7.PubMedPubMedCentral Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7.PubMedPubMedCentral
18.
go back to reference Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.PubMedPubMedCentral Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.PubMedPubMedCentral
19.
go back to reference Luo D, Wan X. Liu J, Tong T: Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805.PubMed Luo D, Wan X. Liu J, Tong T: Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805.PubMed
20.
go back to reference Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedPubMedCentral Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedPubMedCentral
21.
go back to reference Miyagawa S, Kawasaki S, Makuuchi M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology (Baltimore, MD). 1996;24(2):307–10.PubMed Miyagawa S, Kawasaki S, Makuuchi M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology (Baltimore, MD). 1996;24(2):307–10.PubMed
22.
go back to reference Shiraishi M, Hiroyasu S, Nagahama M, Tomita S, Miyahira T, Kusano T, Furukawa M, Muto Y. Characteristics of hepatocellular carcinoma in patients with negative virus markers: clinicopathologic study of resected tumors. World J Surg. 1999;23:301–5.PubMed Shiraishi M, Hiroyasu S, Nagahama M, Tomita S, Miyahira T, Kusano T, Furukawa M, Muto Y. Characteristics of hepatocellular carcinoma in patients with negative virus markers: clinicopathologic study of resected tumors. World J Surg. 1999;23:301–5.PubMed
23.
go back to reference Wu CC, Ho WL, Chen JT, Tang JS, Yeh DC, P’Eng FK. Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma. Br J Surg. 1999;86(11):1391–6.PubMed Wu CC, Ho WL, Chen JT, Tang JS, Yeh DC, P’Eng FK. Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma. Br J Surg. 1999;86(11):1391–6.PubMed
24.
go back to reference Lee WC, Jeng LB, Chen MF. Hepatectomy for hepatitis B-, hepatitis C-, and dual hepatitis B- and C-related hepatocellular carcinoma in Taiwan. J Hepatobiliary Pancreat Surg. 2000;7:265–9.PubMed Lee WC, Jeng LB, Chen MF. Hepatectomy for hepatitis B-, hepatitis C-, and dual hepatitis B- and C-related hepatocellular carcinoma in Taiwan. J Hepatobiliary Pancreat Surg. 2000;7:265–9.PubMed
25.
go back to reference Noguchi K, Nakashima O, Nakashima Y, Shiota K, Nawata H, Kojiro M. Clinicopathologic study on hepatocellular carcinoma negative for hepatitis B surface antigen and antibody to hepatitis C virus Int J Mol. Med Clin. 2000;6:661–5. Noguchi K, Nakashima O, Nakashima Y, Shiota K, Nawata H, Kojiro M. Clinicopathologic study on hepatocellular carcinoma negative for hepatitis B surface antigen and antibody to hepatitis C virus Int J Mol. Med Clin. 2000;6:661–5.
26.
go back to reference Ahmad SA, Bilimoria MM, Wang XM, Izzo F, Delrio P, Marra P, Baker TP, Porter GA, Ellis LM, Vauthey JN, et al. Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma. J Gastrointest Surg. 2001;5(5):468–76.PubMed Ahmad SA, Bilimoria MM, Wang XM, Izzo F, Delrio P, Marra P, Baker TP, Porter GA, Ellis LM, Vauthey JN, et al. Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma. J Gastrointest Surg. 2001;5(5):468–76.PubMed
27.
go back to reference Pawlik TM, Poon RT, Abdalla EK, Sarmiento JM, Ikai I, Curley SA, Nagorney DM, Belghiti J, Ng IO, Yamaoka Y, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg. 2004;8(7):794–804 discussion 804–795.PubMed Pawlik TM, Poon RT, Abdalla EK, Sarmiento JM, Ikai I, Curley SA, Nagorney DM, Belghiti J, Ng IO, Yamaoka Y, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg. 2004;8(7):794–804 discussion 804–795.PubMed
28.
go back to reference Yokoi Y, Suzuki S, Baba S, Inaba K, Konno H, Nakamura S. Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. J Gastroenterol. 2005;40(3):274–82.PubMed Yokoi Y, Suzuki S, Baba S, Inaba K, Konno H, Nakamura S. Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. J Gastroenterol. 2005;40(3):274–82.PubMed
29.
go back to reference Li Q, Li H, Qin Y, Wang PP, Hao X. Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience. J Gastroenterol Hepatol. 2007;22(11):1936–41.PubMed Li Q, Li H, Qin Y, Wang PP, Hao X. Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience. J Gastroenterol Hepatol. 2007;22(11):1936–41.PubMed
30.
go back to reference Nanashima A, Abo T, Sumida Y, Takeshita H, Hidaka S, Furukawa K, Sawai T, Yasutake T, Masuda J, Morisaki T, et al. Clinicopathological characteristics of patients with hepatocellular carcinoma after hepatectomy: relationship with status of viral hepatitis. J Surg Oncol. 2007;96(6):487–92.PubMed Nanashima A, Abo T, Sumida Y, Takeshita H, Hidaka S, Furukawa K, Sawai T, Yasutake T, Masuda J, Morisaki T, et al. Clinicopathological characteristics of patients with hepatocellular carcinoma after hepatectomy: relationship with status of viral hepatitis. J Surg Oncol. 2007;96(6):487–92.PubMed
31.
go back to reference Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Togo S. Clinical characteristics and surgical outcome in hepatocellular carcinoma without hepatitis B virus surface antigen or hepatitis C virus antibody. Ann Surg Oncol. 2007;14(3):1170–81.PubMed Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Togo S. Clinical characteristics and surgical outcome in hepatocellular carcinoma without hepatitis B virus surface antigen or hepatitis C virus antibody. Ann Surg Oncol. 2007;14(3):1170–81.PubMed
32.
go back to reference Kondo K, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J. Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery. J Gastrointest Surg. 2008;12(3):468–76.PubMed Kondo K, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J. Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery. J Gastrointest Surg. 2008;12(3):468–76.PubMed
33.
go back to reference Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg. 2012;204(3):300–7.PubMed Kaibori M, Ishizaki M, Matsui K, Kwon AH. Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg. 2012;204(3):300–7.PubMed
34.
go back to reference Kim JM, Kwon CHD, Joh J-W, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Outcomes After Curative Hepatectomy in Patients with Non-B Non-C Hepatocellular Carcinoma And Hepatitis B Virus Hepatocellular Carcinoma From Non-Cirrhotic Liver. J Surg Oncol. 2014;110(8):976–81.PubMed Kim JM, Kwon CHD, Joh J-W, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Outcomes After Curative Hepatectomy in Patients with Non-B Non-C Hepatocellular Carcinoma And Hepatitis B Virus Hepatocellular Carcinoma From Non-Cirrhotic Liver. J Surg Oncol. 2014;110(8):976–81.PubMed
35.
go back to reference Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Ochiai T, Nakamura N, Arii S, Tanabe M. Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. J Gastroenterol. 2014;49(9):1352–61.PubMed Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Ochiai T, Nakamura N, Arii S, Tanabe M. Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. J Gastroenterol. 2014;49(9):1352–61.PubMed
36.
go back to reference Ochiai T, Ogino S, Ishimoto T, Toma A, Yamamoto Y, Morimura R, Ikoma H, Otsuji E. Prognostic Impact of Hepatectomy for Patients with Non-hepatitis B Non-hepatitis C Hepatocellular Carcinoma. Anticancer Res. 2014;34(8):4399–410.PubMed Ochiai T, Ogino S, Ishimoto T, Toma A, Yamamoto Y, Morimura R, Ikoma H, Otsuji E. Prognostic Impact of Hepatectomy for Patients with Non-hepatitis B Non-hepatitis C Hepatocellular Carcinoma. Anticancer Res. 2014;34(8):4399–410.PubMed
37.
go back to reference Okuda Y, Mizuno S, Shiraishi T, Murata Y, Tanemura A, Azumi Y, Kuriyama N, Kishiwada M, Usui M, Sakurai H, et al. Clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C hepatocellular carcinoma patients with comparison to hepatitis B or C virus. Biomed Res Int. 2014;2014:975380.PubMedPubMedCentral Okuda Y, Mizuno S, Shiraishi T, Murata Y, Tanemura A, Azumi Y, Kuriyama N, Kishiwada M, Usui M, Sakurai H, et al. Clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C hepatocellular carcinoma patients with comparison to hepatitis B or C virus. Biomed Res Int. 2014;2014:975380.PubMedPubMedCentral
38.
go back to reference Zhou YM, Zhang XF, Li B, Sui CJ, Yang JM. Prognosis after resection of hepatitis B virus-related hepatocellular carcinoma originating from non-cirrhotic liver. Ann Surg Oncol. 2014;21(7):2406–12.PubMed Zhou YM, Zhang XF, Li B, Sui CJ, Yang JM. Prognosis after resection of hepatitis B virus-related hepatocellular carcinoma originating from non-cirrhotic liver. Ann Surg Oncol. 2014;21(7):2406–12.PubMed
39.
go back to reference Takeishi K, Maeda T, Shirabe K, Tsujita E, Yamashita Y, Harimoto N, Itoh S, Ikegami T, Yoshizumi T, Maehara Y. Clinicopathologic Features and Outcomes of Non-B, Non-C Hepatocellular Carcinoma After Hepatectomy. Ann Surg Oncol. 2015;22(Suppl 3):S1116–1124.PubMed Takeishi K, Maeda T, Shirabe K, Tsujita E, Yamashita Y, Harimoto N, Itoh S, Ikegami T, Yoshizumi T, Maehara Y. Clinicopathologic Features and Outcomes of Non-B, Non-C Hepatocellular Carcinoma After Hepatectomy. Ann Surg Oncol. 2015;22(Suppl 3):S1116–1124.PubMed
40.
go back to reference Yamashita Y, Imai D, Bekki Y, Kimura K, Matsumoto Y, Nakagawara H, Ikegami T, Yoshizumi T, Shirabe K, Aishima S, et al. Surgical Outcomes of Hepatic Resection for Hepatitis B Virus Surface Antigen-Negative and Hepatitis C Virus Antibody-Negative Hepatocellular Carcinoma. Ann Surg Oncol. 2015;22(7):2279–85.PubMed Yamashita Y, Imai D, Bekki Y, Kimura K, Matsumoto Y, Nakagawara H, Ikegami T, Yoshizumi T, Shirabe K, Aishima S, et al. Surgical Outcomes of Hepatic Resection for Hepatitis B Virus Surface Antigen-Negative and Hepatitis C Virus Antibody-Negative Hepatocellular Carcinoma. Ann Surg Oncol. 2015;22(7):2279–85.PubMed
41.
go back to reference Zhang ZM, Zhang YM, Yao F, Yi P, Huang S, Liu JY, Xiang BD, Yuan WP, Li LQ. Analysis on Postoperative Efficacy of Radical Hepatectomy for Patients with Non-HBV/HCV Hepatocellular Carcinoma. Asian Pac J Cancer Prev. 2015;16(8):3479–83.PubMed Zhang ZM, Zhang YM, Yao F, Yi P, Huang S, Liu JY, Xiang BD, Yuan WP, Li LQ. Analysis on Postoperative Efficacy of Radical Hepatectomy for Patients with Non-HBV/HCV Hepatocellular Carcinoma. Asian Pac J Cancer Prev. 2015;16(8):3479–83.PubMed
42.
go back to reference Li Z, Zhao X, Jiang P, Xiao S, Wu G, Chen K, et al. HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: a retrospective case-control study. Medicine. 2016;95(31):e4224. Li Z, Zhao X, Jiang P, Xiao S, Wu G, Chen K, et al. HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: a retrospective case-control study. Medicine. 2016;95(31):e4224.
43.
go back to reference Wakiyama S, Matsumoto M, Haruki K, Gocho T, Sakamoto T, Shiba H, Futagawa Y, Ishida Y, Yanaga K. Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma. Anticancer Res. 2017;37(6):3207–13.PubMed Wakiyama S, Matsumoto M, Haruki K, Gocho T, Sakamoto T, Shiba H, Futagawa Y, Ishida Y, Yanaga K. Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma. Anticancer Res. 2017;37(6):3207–13.PubMed
44.
go back to reference Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Uesaka K. The Impact of the Hepatitis B Core Antibody Status on Recurrence in Patients with Non-B Non-C Hepatocellular Carcinoma after Curative Surgery. Dig Surg. 2018;35(3):243–51.PubMed Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Uesaka K. The Impact of the Hepatitis B Core Antibody Status on Recurrence in Patients with Non-B Non-C Hepatocellular Carcinoma after Curative Surgery. Dig Surg. 2018;35(3):243–51.PubMed
45.
go back to reference Wu S-S, Shan Q-Y, Xie W-X, Chen B, Huang Y, Guo Y, Xie X-Y, Lu M-D, Peng B-G, Kuang M, et al. Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma. Clin Transl Oncol. 2020;22(3):401–10.PubMed Wu S-S, Shan Q-Y, Xie W-X, Chen B, Huang Y, Guo Y, Xie X-Y, Lu M-D, Peng B-G, Kuang M, et al. Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma. Clin Transl Oncol. 2020;22(3):401–10.PubMed
46.
go back to reference Xue X, Liao W, Xing Y. Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma. Infect Agent Cance. 2020;15:11. Xue X, Liao W, Xing Y. Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma. Infect Agent Cance. 2020;15:11.
47.
go back to reference Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13(2):123–35.PubMed Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13(2):123–35.PubMed
48.
go back to reference Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62.PubMed Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62.PubMed
49.
go back to reference El-Serag HB. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1261.PubMed El-Serag HB. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1261.PubMed
50.
go back to reference Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160274.PubMed Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160274.PubMed
51.
go back to reference Moris D, Tsilimigras DI, Kostakis ID, Ntanasis-Stathopoulos I, Shah KN, Felekouras E, Pawlik TM. Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol. 2018;44(7):927–38.PubMed Moris D, Tsilimigras DI, Kostakis ID, Ntanasis-Stathopoulos I, Shah KN, Felekouras E, Pawlik TM. Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol. 2018;44(7):927–38.PubMed
52.
go back to reference Ishizaki M, Ashida K, Higashi T, Nakatsukasa H, Kaneyoshi T, Fujiwara K, Nouso K, Kobayashi Y, Uemura M, Nakamura S, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch. 2001;438(6):574–80.PubMed Ishizaki M, Ashida K, Higashi T, Nakatsukasa H, Kaneyoshi T, Fujiwara K, Nouso K, Kobayashi Y, Uemura M, Nakamura S, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch. 2001;438(6):574–80.PubMed
53.
go back to reference Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010;45(2):146–52.PubMed Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010;45(2):146–52.PubMed
54.
go back to reference Jiao S, Li G, Zhang D, Xu Y, Liu J, Li G. Anatomic versus non-anatomic resection for hepatocellular carcinoma, do we have an answer? A meta-analysis. Int J Surg (London, England). 2020;80:243–55. Jiao S, Li G, Zhang D, Xu Y, Liu J, Li G. Anatomic versus non-anatomic resection for hepatocellular carcinoma, do we have an answer? A meta-analysis. Int J Surg (London, England). 2020;80:243–55.
Metadata
Title
Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis
Authors
Bingran Yu
Xuting Zhi
Qiong Li
Tao Li
Zhiqiang Chen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02925-x

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.